Imidazopyridyl compounds as aldosterone synthase inhibitors

US9173873B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Amjad Ali · Freehold, US
• D. Jonathan Bennett · Boston, US
• Jaiqiang Cai · Glasgow, GB
• Emma Carswell · Eaglesham, GB
• Andrew Cooke · Doylestown, US
• Scott B. Hoyt · Hoboken, US
• Michael Man-Chu Lo · Rahway, US
• Clare London · Chatham, US
• John MacLean · Brookline, US
• Min K. Park · Whippany, US
• Paul Ratcliffe · Lanark, GB
• Jerry Andrew Taylor · Trenton, US
• Brent Whitehead · Piscataway, US
• Yusheng Xiong · Newtown, US

Key dates

• Filing date: Sep 17, 2012
• Grant date: Nov 3, 2015
• Expiry date: Sep 17, 2032

Classification

• Technology area (CPC —): General

Abstract

This invention relates to imidazopyridyl compounds of the structural formula: I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.